Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Numbing condoms could be a Game-Changer for quick ejaculation

NCT ID NCT05840172

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether condoms containing a mild numbing agent (benzocaine) help men who feel they ejaculate too quickly last longer during vaginal sex. Three hundred healthy adult men in stable relationships tried two types of medicated condoms and one regular condom, recording how long they lasted each time. The goal was to see if the numbing condoms increased time to ejaculation compared to standard condoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

Oct 2023

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: 1. Subjects and their female partners have provided written informed consent. 2. Subjects and their female partners between the ages of \>= 18 years and =\< 60 years. 3. Subjects and their female partners must have no health condition in their medical history. 4. Subject must be sexually active having regular intercourse. 5. Subjects in a stable, monogamous, sexual relationship with the same female partner for more than or equal to 3 months. 6. Subject's female partner should already be on an established other highly effective form of non-barrier contraception, unless post-menopausal. 7. Subjects reporting a frequency of 'occasionally' to the Sexual Intercourse Self-Estimation Scale. Main Exclusion Criteria: 1. Subject with a pregnant or breastfeeding female partner or the female partner desires to become pregnant during the clinical investigation. 2. Subject or his female partner with a current history of alcohol or drug abuse. 3. Subjects and their female partners with a history of or are suffering from anemia, coronary artery disease, impaired cardiac conduction, pulmonary disease, diabetes, and renal or hepatic disease. 4. Subjects and their female partners with a history of, suspected to have, or be at increased risk of methaemoglobinemia / complications related to ester anaesthetics which could trigger methemoglobinemia. 5. Subject and/or his female partner have a physical or psychological condition that would prevent them from following investigation procedures - including but not limited to the following: 1. urological disease, 2. ongoing significant psychiatric disorder not controlled by medication 3. history of surgery or injury to the pelvis, retroperitoneal surgery, radiotherapy, multiple sclerosis, spinal cord injury, chronic inflammation of the prostate or urethra 4. relevant previous or planned genital surgery 5. female partner that has been diagnosed with or treated for vaginal complaints (including vaginal dryness) 6. any broken skin or wounds in the genital area. 6. Subjects on medication that is contraindicated, which may affect erection. 7. Subject and/or his female partner have any medication which may affect the safety of the subject, including but not limited to benzocaine drug interactions such as cholinesterase inhibitors. 8. Subject and/or his female partner is using or intends to continue to use antibiotics of the sulphonamide type. 9. Subject with premature ejaculation, erectile dysfunction, hypo or hyperthyroidism, hypogonadism, hyperprolactinemia, ejaculatory dysfunction, haemorrhagic disorder, hepatitis B or C, human immunodeficiency virus (HIV) infection or having had penile implant surgery. 10. Subject that has been diagnosed or received treatment for PE (premature ejaculation). 11. Subjects with confirmed erectile dysfunction, hypo or hyperthyroidism, hypogonadism, hyperprolactinemia. 12. Confirmed diagnosis of male subjects with other forms of ejaculatory dysfunction. 13. Subjects that have had prior genital, prostatic or lower tract surgery. 14. Subjects with haemorrhagic disorder, hepatitis B or C, HIV infection or having had penile implant surgery, at any time in their past. 15. Either partner needed to use condoms for a specific STI protection. 16. Subjects and their female partners who have any relevant history of allergy including local anaesthetics, parabens, PABA, commercial hair dyes, paraphenylenediamine, lubricants and latex.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ejaculation delayed are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ejaculatory Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • SGS proderm GmbH

    Hamburg, Germany